NL-OMON50157已完成4 期
ASsesment of Platelet function and Inhibition in patients Recovering from severe INfection - ASPIRIN-trial
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 97
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in the main-trial, a subject must meet
- •all of the following criteria:
- •Primary clinical diagnosis of pneumonia
- •Primary clinical diagnosis of invasive urinary tract infection
- •Primary clinical diagnosis of cutaneous infection
- •18 years or older on the date of hospital presentation
- •Hospitalization for at least 24 hours
- •Having received at least 1 dose of antibiotics within 48 hours of admission.
- •In order to be eligible to participate in the sub-study, a subject must meet
- •all of the following criteria:
- •Primary clinical diagnosis of pneumonia
- •Primary clinical diagnosis of invasive urinary tract infection
- •Primary clinical diagnosis of cutaneous infection
- •18 years or older on the date of hospital presentation
- •Hospitalization for at least 24 hours
- •Having received at least 1 dose of antibiotics within 48 hours of admission
- •Known stable cardiovascular disease. Stable cardiovascular disease defined as:
- •coronary artery disease, peripheral vascular disease, or previous myocardial
- •infarction (>12 months).
- •Chronic usage of 80 mg of non-enteric coated acetylsalicylic acid once daily in
- •the morning.
排除标准
- •A potential subject who meets any of the following criteria will be excluded
- •from participation in the main-trial:
- •- Active metastatic cancer (c.q. malignancy)
- •- Allergy to salicylate
- •- Platelet count <120*109/l
- •- History of non-traumatic major bleeding
- •- Known bleeding diathesis
- •- Conditions which require antiplatelet therapy
- •- Usage of antiplatelet therapy
- •- Surgery 1 month prior to diagnosis
- •- Currently pregnant
- •- Chronic usage of medication which are known to influence platelet function
- •other than antibiotics (e.g. NSAID*s, tirofiban, eptifibatide, abciximab,
- •SSRI*s, clomipramine, amitriptyline, dipyridamole, verapamil, diltiazem ,
- •ginkgo biloba, ginseng, & St John*s wort)
- •A potential subject who meets any of the following criteria will be excluded
- •from participation in the sub-study:
- •- Active metastatic cancer (c.q. malignancy)
- •- Platelet count <120*109/l
- •- History of non-traumatic major bleeding
- •- Known bleeding diathesis
- •- Surgery 1 month prior to diagnosis
- •- Currently pregnant
- •- Chronic usage of medication which are known to influence platelet function
- •other than antibiotics or aspirin (e.g. NSAID*s, tirofiban, eptifibatide,
- •abciximab, SSRI*s, clomipramine, amitriptyline, dipyridamole, verapamil,
- •diltiazem , ginkgo biloba, ginseng, & St John*s wort)
研究者
相似试验
进行中（未招募）
1 期
Evaluation of platelet activity in patients recovering from a severe infectioHyperaggregability of thrombocytes triggered by severe infection (i.e. pneumonia or invasive urinary tract infection or a cutaneous infection).EUCTR2016-004303-32-NLVU university medical center62
招募中
不适用
Platelet-activation and optimal inhibition in patients with Atrial Fibrillation undergoing LAA closure; The POPULAR-LAAO trialAfib10007521Atrial fibrillationNL-OMON49947Sint Antonius Ziekenhuis120
已完成
不适用
Inhibitory efficacy in platelet aggregation and pharmacokinetics of single oral administration of 300mg clopidogrel and 20mg prasugrelIschemic heart diseases with PICJPRN-UMIN000014161Kazuo Umemura Center for clinical research Hamamatsu University Hospital50
尚未招募
4 期
The magnitude of platelet inhibition and the pharmacokinetics of a 600 mg loading dose of clopidogrel, in different patient categories (stable angina versus acute-coronary syndromes versus ST-elevated myocardial infarction).patients with a history of a stent thrombosis1003553410011082NL-OMON33697Cardiology200
已完成
2 期
A Study of Acute Coronary Syndrome PatientsCTRI/2010/091/000348Eli Lilly210